Accepted Articles
Back to the articles list |
Back to browse issues page
Shayan Bahadivand Chegini1 
, Zahra Taslimi2 , Erfan Ayubi3 , Salman Khazaei4 , Saeid Yazdi_Ravandi5 , Helen Behmanesh6 , Fatemeh Esmaeili1 , Mona Doostizadeh *5
, Zahra Taslimi2 , Erfan Ayubi3 , Salman Khazaei4 , Saeid Yazdi_Ravandi5 , Helen Behmanesh6 , Fatemeh Esmaeili1 , Mona Doostizadeh *5
1- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
2- Behavioral Disorders and Substance Abuse Research Center, Institute of Neuroscience and Mental Health, Hamadan University of Medical Sciences2. Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
3- Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
4- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran & Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
5- Behavioral Disorders and Substance Abuse Research Center, Institute of Neuroscience and Mental Health, Hamadan University of Medical Sciences, Hamadan, Iran.
6- Autism Spectrum Disorders Research Center, Hamadan University of medical sciences, Hamadan, Iran
2- Behavioral Disorders and Substance Abuse Research Center, Institute of Neuroscience and Mental Health, Hamadan University of Medical Sciences2. Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
3- Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
4- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran & Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
5- Behavioral Disorders and Substance Abuse Research Center, Institute of Neuroscience and Mental Health, Hamadan University of Medical Sciences, Hamadan, Iran.
6- Autism Spectrum Disorders Research Center, Hamadan University of medical sciences, Hamadan, Iran
Abstract:
Introduction: Substance Use Disorders (SUDs) represent a significant public health issue, particularly among high-risk populations such as drivers. This review aimed to quantify the prevalence of SUDs among diverse driver populations in Iran.
Methods: We followed PRISMA guidelines and conducted a comprehensive literature search using PubMed, Scopus, and Web of Science from 2013 through August 2024. Meta-regression analyses were conducted to explore heterogeneity sources, while subgroup analyses were performed based on data collection methods and demographic factors.
Results: A total thirteen studies were included, revealing an overall pooled prevalence of SUDs among specific groups of Iranian drivers (accident involved, commercial and motorcycles drivers) who were investigated previously at 29% (95% CI: 21% to 37%). Prevalence rates by substance type included opium-based drugs (20%), alcohol (9%), cannabis (8%), sedative-hypnotic drugs (1%), and stimulants (2%). Notably, drivers involved in accidents exhibited a higher prevalence of 36%, compared to 23% for commercial drivers and 13% for motorcyclists. Significant heterogeneity was observed (I² = 98.5%, p<0.001), indicating variability across studies.
Conclusion: The high prevalence of SUDs among drivers in Iran highlights the urgent need for targeted interventions to enhance driver safety and well-being. Further research is essential to address the factors contributing to these elevated rates among specific driver demographics.
Methods: We followed PRISMA guidelines and conducted a comprehensive literature search using PubMed, Scopus, and Web of Science from 2013 through August 2024. Meta-regression analyses were conducted to explore heterogeneity sources, while subgroup analyses were performed based on data collection methods and demographic factors.
Results: A total thirteen studies were included, revealing an overall pooled prevalence of SUDs among specific groups of Iranian drivers (accident involved, commercial and motorcycles drivers) who were investigated previously at 29% (95% CI: 21% to 37%). Prevalence rates by substance type included opium-based drugs (20%), alcohol (9%), cannabis (8%), sedative-hypnotic drugs (1%), and stimulants (2%). Notably, drivers involved in accidents exhibited a higher prevalence of 36%, compared to 23% for commercial drivers and 13% for motorcyclists. Significant heterogeneity was observed (I² = 98.5%, p<0.001), indicating variability across studies.
Conclusion: The high prevalence of SUDs among drivers in Iran highlights the urgent need for targeted interventions to enhance driver safety and well-being. Further research is essential to address the factors contributing to these elevated rates among specific driver demographics.
Type of Study: Original |
Subject:
Behavioral Neuroscience
Received: 2026/05/14 | Accepted: 2026/07/26
Received: 2026/05/14 | Accepted: 2026/07/26
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
